USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment

Oncotarget

Volumn 7, Issue 21, 2016, Pages 30962-30976

  Vogel, Rachel Isaksson ^a   Pulver, Tanya ^a   Heilmann, Wiebke ^a,b   Mooneyham, Ashley ^a   Mullany, Sally ^a   Zhao, Xianda ^c   Shahi, Maryam ^c   Richter, James ^c   Klein, Molly ^c   Chen, Liqiang ^d   Ding, Rui ^d   Konecny, Gottfried ^e   Kommoss, Stefan ^b   Winterhoff, Boris ^a   Ghebre, Rahel ^a   Bazzaro, Martina ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UCLA MEDICAL CENTER   (United States)

Author keywords

Biomarker; Endometrial cancer; Recurrence; USP14; VLX1570

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBOPLATIN; CASPASE 3; DEUBIQUITINASE; KI 67 ANTIGEN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; USP14 PROTEIN; VLX 1570; AZEPINE DERIVATIVE; BENZYLIDENE DERIVATIVE; ENZYME INHIBITOR; TUMOR MARKER; UBIQUITIN THIOLESTERASE; USP14 PROTEIN, HUMAN; VLX1570;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENDOMETRIUM CANCER; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RISK ASSESSMENT; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; ENDOMETRIUM TUMOR; ENZYMOLOGY; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE; TUMOR RECURRENCE;

AGED; AZEPINES; BENZYLIDENE COMPOUNDS; BIOMARKERS, TUMOR; CARBOPLATIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; UBIQUITIN THIOLESTERASE;

EID: 84971517359     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8821     Document Type: Article

References (37)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
2. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY and Pecorelli S. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1:S105-143.
3. Boll D, Karim-Kos HE, Verhoeven RH, Burger CW, Coebergh JW, van de Poll-Franse LV and van Doorn HC. Increased incidence and improved survival in endometrioid endometrial cancer diagnosed since 1989 in The Netherlands: a population based study. Eur J Obstet Gynecol Reprod Biol. 2013; 166:209-214.
4. Dowdy SC, Borah BJ, Bakkum-Gamez JN, Weaver AL, McGree ME, Haas LR, Keeney GL, Mariani A and Podratz KC. Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecologic Oncology. 2012; 127:5-10.
5. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG and Gynecologic Oncology G. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology. 2004; 92:744-751.
6. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology. 1983; 15:10-17.
7. Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Muller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, et al. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. Journal of the National Cancer Institute. 2013; 105:1142-1150.
8. Schirmer U, Fiegl H, Pfeifer M, Zeimet AG, Muller-Holzner E, Bode PK, Tischler V and Altevogt P. Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens. BMC Cancer. 2013; 13:156.
9. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, van den Bergh AC, de Winter KA, Koper PC, Lybeert ML, Slot A, Lutgens LC, Stenfert Kroese MC, Beerman H, van Lent M. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol. 2004; 22:1234-1241.
10. Shinji S, Naito Z, Ishiwata S, Ishiwata T, Tanaka N, Furukawa K, Suzuki H, Seya T, Matsuda A, Katsuta M and Tajiri T. Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. Oncology Reports. 2006; 15:539-543.
11. Wu N, Liu C, Bai C, Han YP, Cho WC and Li Q. Overexpression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of beta-catenin. International Journal of Molecular Sciences. 2013; 14:10749-10760.
12. Wang Y, Wang J, Zhong J, Deng Y, Xi Q, He S, Yang S, Jiang L, Huang M, Tang C and Liu R. Ubiquitin-specific protease 14 (USP14) regulates cellular proliferation and apoptosis in epithelial ovarian cancer. Medical Oncology. 2015; 32:379.
13. Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y, Carrasco RD, Richardson P, Linder S, Chauhan D and Anderson KC. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014; 123:706-716.
14. Wu N, Zhang C, Bai C, Han YP and Li Q. MiR-4782-3p inhibited non-small cell lung cancer growth via USP14. Cellular Physiology and Biochemistry. 2014; 33:457-467.
15. Coughlin K, Anchoori R, Iizuka Y, Meints J, MacNeill L, Vogel RI, Orlowski RZ, Lee MK, Roden RB and Bazzaro M. Small-molecule RA-9 inhibits proteasomeassociated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clinical Cancer Research. 2014; 20:3174-3186.
16. Vogel RI, Coughlin K, Scotti A, Iizuka Y, Anchoori R, Roden RB, Marastoni M and Bazzaro M. Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells. Oncotarget. 2015; 6:4159-4170. doi: 10.18632/oncotarget.2904.
17. Stuart-Harris R, Caldas C, Pinder SE and Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32, 825 patients. Breast. 2008; 17:323-334.
18. de Azambuja E, Cardoso F, de Castro G, Jr., Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ and Paesmans M. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients. Br J Cancer. 2007; 96:1504-1513.
19. Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, Edler L, Munch M, Muller-Holzner E, Jerabek-Klestil S, Abdel-Azim S, Marth C, Zeimet AG, Altevogt P and Fogel M. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. The Journal of Pathology. 2010; 220:551-561.
20. Nguyen H, Sevin B, Averette H, Perras J, Ramos R, Angioli R and Ochiai K. Comparison of cytotoxicity and cell kinetic perturbations of 5 platinum compounds in gynecologic cancer cell-lines. International Journal of Oncology. 1993; 3:375-382.
21. Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, Bristow RE, Mazitschek R, Bradner J and Roden RB. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clinical Cancer Research. 2008; 14:7340-7347.
22. Wang X, D'Arcy P, Caulfield TR, Paulus A, Chitta K, Mohanty C, Gullbo J, Chanan-Khan A and Linder S. Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b-AP15. Chemical Biology & Drug Design. 2015; 86:1036-1048.
23. Sarhan D, Wennerberg E, D'Arcy P, Gurajada D, Linder S and Lundqvist A. A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells. Cancer Immunology & Immunotherapy. 2013; 62:1359-1368.
24. D'Arcy P, Brnjic S, Olofsson MH, Fryknas M, Lindsten K, De Cesare M, Perego P, Sadeghi B, Hassan M, Larsson R and Linder S. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nature Medicine. 2011; 17:1636-1640.
25. D'Arcy P and Linder S. Proteasome deubiquitinases as novel targets for cancer therapy. The International Journal of Biochemistry & Cell Biology. 2012; 44:1729-1738.
26. Feng X, Holmlund T, Zheng C and Fadeel B. Proapoptotic effects of the novel proteasome inhibitor b-AP15 on multiple myeloma cells and natural killer cells. Experimental Hematology. 2014; 42:172-182.
27. Hogarty MD. Mcl1 becomes ubiquitin-ous: new opportunities to antagonize a pro-survival protein. Cell Research. 2010; 20:391-393.
28. Opferman JT and Green DR. DUB-le Trouble for Cell Survival. Cancer Cell. 2010; 17:117-119.
29. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang DC and Dixit VM. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2010; 463:103-107.
30. Liu YL, Zheng J, Tang LJ, Han W, Wang JM, Liu DW and Tian QB. The deubiquitinating enzyme activity of USP22 is necessary for regulating HeLa cell growth. Gene. 2015; 572:49-56.
31. Hu J, Yang D, Zhang H, Liu W, Zhao Y, Lu H, Meng Q, Pang H, Chen X, Liu Y and Cai L. USP22 promotes tumor progression and induces epithelial-mesenchymal transition in lung adenocarcinoma. Lung Cancer. 2015; 88:239-245.
32. Fournane S, Krupina K, Kleiss C and Sumara I. Decoding ubiquitin for mitosis. Genes Cancer. 2012; 3:697-711. doi: 10.1177/1947601912473477.
33. Benanti JA. Coordination of cell growth and division by the ubiquitin-proteasome system. Seminars in Cell & Developmental Biology. 2012; 23:492-498.
34. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009; 105:103-104.
35. Sueblinvong T, Ghebre R, Iizuka Y, Pambuccian SE, Isaksson Vogel R, Skubitz AP and Bazzaro M. Establishment, characterization and downstream application of primary ovarian cancer cells derived from solid tumors. PLoS One. 2012; 7:e50519.
36. Anchoori RK, Khan SR, Sueblinvong T, Felthauser A, Iizuka Y, Gavioli R, Destro F, Isaksson Vogel R, Peng S, Roden RB and Bazzaro M. Stressing the ubiquitinproteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells. PLoS One. 2011; 6:e23888.
37. DeLong ER, DeLong DM and Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988; 44:837-845.